Stuart Arbuckle

Mr. Arbuckle has served as a member of our Board of Directors since July 2019. Mr. Arbuckle is currently the Executive Vice President and Chief Operating Officer at Vertex Pharmaceuticals, where he oversees the global commercial team, which is responsible for the company’s reimbursement and access, sales, marketing, patient support, and market research, as well as Vertex’s commercial manufacturing and supply chain functions, and other activities that support the approved use of Vertex’s marketed medicines around the world. Mr. Arbuckle also oversees the Human Resources, Corporate Communications and Program and Portfolio Management functions. Prior to joining Vertex, Mr. Arbuckle held several commercial leadership positions at Amgen, including leading sales and marketing efforts for Amgen’s portfolio of cancer medicines, leading the successful launches of XGEVA® injection and Nplate® injection, and leading efforts to expand the company’s presence in Asia, the Middle East, and Africa. Prior to these roles, Mr. Arbuckle spent 15 years at GlaxoSmithKline, where he held sales and marketing roles for medicines aimed at treating metabolic, respiratory, musculoskeletal, cardiovascular and other diseases. Mr. Arbuckle currently serves as a board member of ImmunoGen and as a national board member of Cancer Support Community, an international non-profit organization dedicated to providing support and education to people affected by cancer. He also serves on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO), where he is co-chair of the BIO Standing Committee on Access & Value. Mr. Arbuckle holds a BS in Pharmacology and Physiology from the University of Leeds in the United Kingdom.